Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11472002 | 0.80 | GPR119 (0.59) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11383040 | 0.78 | GPR119 (0.53) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6866194 | 0.77 | PDE3B (0.53) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL5679123 | 0.77 | PDE3B (0.60) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6402428 | 0.75 | PDE4A (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6402430 | 0.75 | PDE4A (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6403046 | 0.75 | PDE4A (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL1251878 | 0.72 | PDE4A (0.53) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL2591981 | 0.69 | GPR119 (1.00) | GPR119 | |
| SCHEMBL2592363 | 0.69 | GPR119 (1.00) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050059658-A1 | Pyridazinone | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-17 | — | — | US | disclosed |
| EP-1404657-A1 | PYRIDAZINONE | Bayer HealthCare AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003002541-A1 | PYRIDAZINONE | BAYER HEALTHCARE AG (DE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059658-A1 | Pyridazinone | TYMP, TPMT, PDXK | PDE3B 1587/4885PDE3A 1579/4885PDE4A 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.